In a study including 779 colon cancers of all stages and taking into account MS and BRAF status, Wirta et al. [61] found that IS composed of CD3+ and CD8+ TILs was not superior to TNM staging as an independent prognostic factor, yet it could discriminate patients survival within each stage, particularly in stage IIa. Here, BRAF is linked to malignant colon neoplasm.